Sign in Subscribe
Cancer research

Selective Estrogen Receptor Modulator Delivery Triggers Apoptosis in Breast Cancer Cells

Strategic Insights

— 1 min read

Scientists at the University of Illinois have discovered a novel approach to treating breast cancer by delivering quinone warheads to DNA via a selective estrogen receptor modulator (SERM), triggering apoptosis in estrogen receptor-positive (ER+) breast cancer cells. This breakthrough study, published in ACS Chemical Biology, demonstrates the potential for a new cancer therapy. The researchers found that conjugating quinone warheads to the SERM desmethylarzoxifene (DMA) resulted in enhanced cytotoxicity and apoptosis in ER+ breast cancer cells, while maintaining antiestrogenic activity.

Key Takeaways:

  • The study demonstrated the effectiveness of conjugating quinone warheads to the SERM desmethylarzoxifene (DMA) in inducing apoptosis in ER+ breast cancer cells.
  • The conjugates showed enhanced cytotoxicity and apoptosis in ER+ breast cancer cells, while maintaining antiestrogenic activity.
  • The researchers observed ROS production localized in the nucleus for conjugates in ER+ cells, suggesting that the quinone warheads were concentrated in the nucleus through ER binding.
  • The novel conjugation of quinone warheads to an ER-targeting SERM amplified DNA damage induced by catechol estrogen metabolites, independent of hormonal activity.
  • The study suggests that this approach may have potential application in cancer therapy.
  • The researchers, led by K.W. Peng, demonstrated that the conjugates induced apoptosis and activation of caspase-3/7 in ER+ breast cancer cells, while ROS production was localized in the nucleus.

Statistics:

  • The cytotoxicity of the conjugates was increased significantly in ER+ cells compared to DMA and isolated warheads.
  • The apoptosis and activation of caspase-3/7 in ER+ cells were also increased significantly compared to DMA and isolated warheads.
  • The production of ROS was localized in the nucleus for conjugates in ER+ cells, suggesting a concentration of quinone warheads in the nucleus.
  • The study demonstrated a novel approach to delivering quinone warheads to DNA via an ER-targeting SERM, with potential application in cancer therapy.

Sources:

  • ACS Chemical Biology, 2009;4(12):1039-49
  • K.W. Peng et al., University of Illinois
  • University of Illinois, College of Pharmacy, Dept. of Medicinal Chemistry and Pharmacognosy
  • National Center for Biotechnology Information (NCBI)
  • NewsRx.com

Read more